The rosiglitazone controversy: the Indian perspective.
Mohan
V
V
Joshi
Shashank R
SR
D003324:Coronary Artery Disease / Q000139:chemically induced; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology; D004341:Drug Evaluation / Q000592:standards; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007194:India / Q000453:epidemiology; D015201:Meta-Analysis as Topic; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone